Hims & Hers Health Tumbles 3.47% as Analyst Downgrades and Legal Risks Sink $300M Volume to 460th Rank

Market Snapshot

Hims & Hers Health (HIMS) fell 3.47% on March 5, 2026, with a trading volume of $0.30 billion, ranking it 460th in market activity for the day. The decline followed a series of analyst downgrades and mixed financial results, reflecting investor caution ahead of regulatory and business clarity. Despite maintaining an Overweight rating from Barclays and similar assessments from other firms, the stock’s performance underscored concerns over near-term profitability and regulatory risks.

Key Drivers

The stock’s decline was primarily driven by a cascade of analyst actions that reduced price targets while retaining cautious optimism. On February 24, 2026, Barclays cut its target for HIMS to $25 from $48, TD Cowen’s Jonna Kim lowered hers to $17 from $20, and Morgan Stanley’s Craig Hettenbach reduced his to $21 from $40. All three maintained their Overweight or Equal Weight ratings, signaling long-term confidence but acknowledging near-term headwinds. These adjustments reflected analysts’ concerns over regulatory uncertainty, particularly around compounded injectable GLP-1s, and the company’s EBITDA guidance, which fell 8% below consensus.

Hims & Hers Health’s Q4 2025 results further fueled investor skepticism. While revenue of $617.82 million matched the $617.25 million consensus, earnings per share (EPS) came in at 8 cents versus the 19 cents expected. The shortfall highlighted operational pressures, despite CEO Andrew Dudum’s emphasis on subscriber growth (2.5 million) and international expansion. Dudum cited progress in 2025, including hormone therapies, diagnostics, and “Labs” initiatives, but analysts questioned whether these diversification efforts would offset near-term EBITDA underperformance.

Regulatory risks intensified following Novo Nordisk’s lawsuit against Hims & Hers Health over alleged patent infringement related to compounded semaglutide. Canaccord Genuity lowered its price target from $68 to $30 in response, while the FDA’s proposed restrictions on non-FDA-approved compounded GLP-1s added to operational uncertainty. Analyst Maria Ripps noted the lawsuit increases risk but stopped short of revising financial estimates. These developments, combined with TD Cowen’s emphasis on “clarity on regulatory implications,” suggest that legal and compliance challenges will remain a drag on investor sentiment until resolved.

The company’s strategic initiatives, however, present a counterbalance to these challenges. Dudum highlighted international expansion and platform diversification as strengths, including the launch of hormone therapies and diagnostics. These moves align with Hims & Hers Health’s vision to become a global leader in consumer health, yet analysts remain skeptical about their near-term impact on profitability. The gap between revenue performance and EBITDA expectations—despite 2% revenue guidance above consensus—signals ongoing investment in growth, which may not resonate with investors prioritizing short-term margins.

Collectively, these factors illustrate a stock at a crossroads. Analysts acknowledge Hims & Hers Health’s long-term potential in the telehealth sector but are recalibrating valuations to account for regulatory, legal, and operational risks. While the company’s subscriber base and international ambitions are compelling, the near-term outlook hinges on resolving GLP-1-related legal disputes, improving EBITDA margins, and demonstrating clearer traction from its diversification efforts. For now, the market appears to price in prolonged uncertainty, reflected in the 3.47% decline and reduced analyst price targets.